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Context: Only approximately 85% of patients with a clinical diagnosis complete androgen insen-
sitivity syndrome and less than 30%with partial androgen insensitivity syndrome can be explained
by inactivating mutations in the androgen receptor (AR) gene.
Objective: The objective of the studywas to clarify this discrepancy by in vitro determination of AR
transcriptional activity in individuals with disorders of sex development (DSD) and male controls.
Design: Quantification of DHT-dependent transcriptional induction of the AR target gene apoli-
poprotein D (APOD) in cultured genital fibroblasts (GFs) (APOD assay) and next-generation se-
quencing of the complete coding and noncoding AR locus.
Setting: The study was conducted at a university hospital endocrine research laboratory.
Patients:GFs from 169 individuals were studied encompassing control males (n 68), molecular defined
DSD other than androgen insensitivity syndrome (AIS; n  18), AR mutation-positive AIS (n  37), and
previously undiagnosed DSD including patients with a clinical suspicion of AIS (n 46).
Intervention(s): There were no interventions.
Main Outcome Measure(s): DHT-dependent APOD expression in cultured GF and AR mutation
status in 169 individuals was measured.
Results:TheAPODassayclearly separatedcontrol individuals (healthymalesandmoleculardefined
DSDpatients other thanAIS) fromgenetically provenAIS (cutoff2.3-foldAPOD-induction; 100%
sensitivity, 93.3% specificity, P .0001). Of 46 DSD individuals with no ARmutation, 17 (37%) fell
below the cutoff, indicating disrupted androgen signaling.
Conclusions:ARmutation-positiveAIS canbe reliably identifiedby theAPODassay. Its combination
with next-generation sequencing of the AR locus uncovered an ARmutation-negative, new class
of androgen resistance, which we propose to name AIS type II. Our data support the existence of
cellular components outside the AR affecting androgen signaling during sexual differentiation
with high clinical relevance. (J Clin Endocrinol Metab 101: 4468–4477, 2016)
Sexual development is a complex process involvingthree crucial steps: development of the gonads in the
embryo, synthesis of sex hormones, and sex hormone ac-
tion. Genetic errors in any of these processes can lead to a
wide range of sexual phenotypes that can be broadly in-
cluded under the umbrella term of disorders of sex devel-
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opment (DSD) (1–3). Androgen insensitivity syndrome
(AIS) (online inheritance inmannumber300068) is aDSD
that is classically characterized as a disorder of hormone
action due to a reduced or absent functionality of the an-
drogen receptor (AR)protein encodedby theAR gene.AIS
is often suspected to be a common cause of DSD in a
46,XY individual and may be associated with complete
feminization of the external genitalia due to a complete
lack of AR transcriptional activity (complete AIS [CAIS])
(4), a variable level of feminization/masculinization due to
a partial lack of transcriptional activity (partial AIS
[PAIS]), or isolated male infertility (mild AIS [MAIS]).
For optimal function, the AR is activated through its
ligands, T and the more potent DHT, after which it trans-
locates into the nucleus and binds to its target geneswhose
expression entails the development of male internal and
external genitalia. This process is tightly regulated
through coactivators and corepressors of the AR (5, 6).
Many AR target genes have been described in prostate
cancer-derived cell lines; however, only a handful of genes
have been identified in healthy male genital tissue (7).
Among these, apolipoprotein D (APOD) has been re-
ported to exhibit the most significant induction upon
DHTtreatment.APOD is a direct transcriptional target of
the AR (8, 9), and a DHT-dependent secretion of APOD
has been observed in prostate cancer cells (10). APOD
belongs to the lipocalin protein family (11) and is able to
carryE-3-methyl-2-hexenoic acid, the most abundant ax-
illary odorant in males, to the skin surface ultimately used
for pheromonal communication (12).
Whereas the clinical diagnosis of CAIS is relatively
easy and can be confirmed by identifying a genetic ab-
normality in theAR coding sequence (AR-CDS) in more
than 85%of cases, the clinical diagnosis of PAIS is more
difficult, and, in addition, less than 30% of cases that
are clinically suspected of PAIS are associated with a
mutation in the AR (13). It is not known whether some
individuals with 46,XY DSD may, in fact, have a cur-
rently unidentified new class of androgen insensitivity
despite the absence of an AR-CDS mutation or whether
some, or even all, rather have normal cellular AR func-
tion, thus excluding AIS.
To understand the possible coexistence of androgen
resistance without any genetic evidence of a defect in the
AR, we analyzed a cohort of 169 individuals including
male controls, individuals with genetically proven AIS,
and individuals with a clinical suspicion but no molecular
proof of AIS in whom genital fibroblasts were available.
Combining AR-sequencing analysis with a functional as-
say for AR activity by measuring the DHT-dependent
transcriptional induction of the androgen-regulated
APOD gene in cultured genital fibroblasts (GF) (APOD
assay) enabled us to discover a newARmutation-negative
class of androgen resistance, which we propose to name
AIS type II.
Materials and Methods
The study was performed in agreement with the vote of the Eth-
ical Committee of the Medical Faculty of the Christian-Al-
brechts-University (Kiel, Germany; AZ: D415/11; File S1). GFs
received from collaborating partners were included in this study
according to the recommendations of the local ethical commit-
tees. All GFs included in this study were double encrypted and
numbered from 1 to 169.
Sample collection
The GFs herein analyzed belonged to four major clinical
groups.
The first group (group 1) was established in collaboration
with local urologists and pediatric surgeons and includes scro-
tum-derived control GFs from fertile adult patients with normal
virilization of the external genitalia, who underwent vasectomy
(n 30). We included scrotal biopsies of patients under the age
of 18 years who underwent orchidopexy due to maldescended
testes (n  13) with normal external genitalia, ie, no hypospa-
dias. In addition, we used control foreskin fibroblasts from pa-
tients who underwent circumcision due to cultural reasons or
phimosis (n25).GenomicDNAof allmale controlGF cultures
was sequenced using our custom haloplex next-generation se-
quencing (NGS) panel including up- anddownstream sequences,
untranslated regions, and the introns (Figure 1A).
The second group consists of GFs from previously character-
ized 46,XYDSD individuals with a defined molecular diagnosis
other than AIS (group 2). In particular, these individuals carried
mutations in the steroidogenic factor 1 gene (NR5A1) (n  2),
the 17-hydroxylase gene (CYP17A1) (n 2), the 17-hydrox-
ysteroid-dehydrogenase type III gene (HSD17B3) (n  4), and
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the 5-reductase type II gene (SRD5A2) (n  8) in conjunction
with ambiguousor female external genitalia. Biopsieswere taken
from either labioscrotal or foreskin/labia minora tissue. We
added GFs from female (46,XX) individuals with congenital ad-
renal hyperplasia due to 21-hydroxylase deficiency (CYP21A2)
(n  2). Genomic DNA derived from the GF cultures of the
second group was sequenced via the custom haloplex NGS AR
panel.
The third group contains labioscrotal and foreskin/labia mi-
nora-derived GFs with a genetic proof of AIS, in whommutations
in theAR-CDSwere either found previously via Sanger sequencing
or in this paper through thehaloplexNGSARpanel (n37; group
A
B
C
D
Figure 1. NGS of the AR locus. A, Graphic representation of the AR locus and the regions amplified by the haloplex design (chrX: 66,754,874–
66955461 [hg19]) (shown in green). Highly repetitive sequences were excluded from the design (shown in brown). For comparison, repetitive
elements present in this locus are shown in black. B, Division of the four patient groups from whom cultured GFs were analyzed. When mutations
were found in the AR-CDS of GFs from group 4 (clinically suspected androgen resistance), they were reallocated to group 3 (genetically proven
AIS). Therefore, two of the initially 41 samples from group 4 with clinically suspected PAIS and seven of the initially eight samples with clinically
suspected CAIS were reallocated to group 3, resulting in 15 GF samples with genetically proven PAIS and 22 samples with genetically proven CAIS,
respectively. C, Distribution of mutations found in the CDS of the AR. Red dots represent nonsense mutations and green dots missense mutations.
Synonymous mutations in the coding region were not considered as CDS mutations. The graph was designed using the Mutation Mapper
software from cBioPortal. D, Distribution of nonannotated SNPs along the sequenced region (green bars). DNTD, N-terminal transactivation
domain; DBD, DNA-binding domain; HR, hinge region; LBD, ligand-binding domain.
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3).AllGFs that revealed anAR-CDSmutation via the customhalo-
plex NGS AR panel were validated by Sanger sequencing.
The fourth group was compiled from a collection of labios-
crotal and foreskin/labia minora-derived GF samples from
46,XY DSD individuals without an established molecular diag-
nosis (group 4). It includes individuals with apparently unaf-
fected androgen biosynthesis based on available hormone data
supporting a clinical suspicion of androgen resistance (n 46).
When available, data on the external genital appearance, basal
and stimulated T levels (HCG test), and measurements on AR
ligand binding (maximal binding capacity and dissociation con-
stant) were collected (Supplemental Tables 1 and 2). This group
may also contain individuals with a yet-undiagnosed form of
DSDother thanAIS. All GFs of group 4were sequenced through
our customhaloplexNGSARpanel. If anAR-CDSmutationwas
detected by NGS, Sanger sequencing was used for confirmation
and the GFs were subsequently reallocated to group 3.
Supplemental Table 3 lists all GFs included in this study ac-
cording to their location of biopsy together with the median age
at biopsy.
Primary culturing of genital skin biopsies, the APOD assay,
NGS library preparation, sequencing, and further methods are
described in the SupplementalMaterial, including Supplemental
Figures 1–7.
Results
Separation of GF into AR coding sequence
mutation-positive and -negative entities
In the group of male controls (group 1), no mutations
were detected in the coding sequence (CDS) and the in-
tron-exon boundaries of the AR. In group 2 (molecular
definedDSDdiagnoses other thanAIS), therewere also no
AR-CDS or intron-exon boundary mutations. In all clas-
sicalAIS individuals (genetically provenAIS, group3) pre-
viously identified by Sanger sequencing, mutations in the
AR-CDScouldbe validatedbyour customNGSARpanel,
underlining the validity of the NGS approach. All those
individuals in group 4with previously undiagnosed forms
of DSD in whomwe identified a mutation in theAR-CDS
by NGS (n  9) were reallocated to group 3. In the re-
mainingGF samples of group 4, includingDSD samples in
whichAISwas suspected (n46), neithermutations in the
AR-CDS nor in the intron-exon boundaries could be de-
tected. A schematic representation of all four groups is
shown in Figure 1B. The distribution of detectedAR-CDS
mutationswithin group3 is schematically shown inFigure
1C, and their exact position is listed in SupplementalTable
4. EightAR-CDSmutations are not currently listed in the
AR mutation database (14) and, to our knowledge, have
not been described in the literature. These unreportedmu-
tations are frameshift mutations (n  5), stop mutations
(n  1), and missense mutations (n  2) (Supplemental
Table 4). Outside the coding region, numerous nonanno-
tated single-nucleotidepolymorphisms (SNPs)were found
in all four groups. A distribution of those SNPs is shown
in Figure 1D.
Calculation of a cutoff for the functional
classification of male controls (group 1),
molecular-defined DSD other than AIS (group 2),
and AR-CDS mutation-positive AIS individuals
(group 3) using the APOD assay
We now functionally characterized all 169 sequenced
GF by measuring the DHT-triggered ability of the AR to
induce transcription of its target gene APOD (APOD as-
say).Male control scrotum-derivedGFs fromgroup 1 (va-
sectomy, orchidopexy) showed a mean DHT-mediated
APOD induction of 3.5-fold (SD 0.85), defining the nor-
mal range of transcriptional function of the AR in this
group (Figure 2A). Scrotum-derived GFs from group 2
(molecular defined DSD other than AIS) showed the same
degree of APOD up-regulation, confirming uncompro-
mised functionality of the AR in these cells (Figure 2A).
Only one orchidopexy-derived control GF cell line from
an individual in group 1 showed an unexpectedly low in-
duction of APOD. In the light of the complete data set
provided in this manuscript and because the final steps of
the testicular descent are androgen dependent, we retro-
spectively have to conclude that this individual has some
degree of androgen resistance (15). In contrast to groups
1 and 2,APOD induction was significantly lower in scro-
tum-derived GFs from classical AIS individuals (group 3)
(P  .001). CAIS-derived GFs showed on average no in-
duction (0.96), whereas PAIS-derived GFs demonstrated
an average induction of 1.62 (Figure 2A). This confirms
androgen resistance at the functional molecular level in
these cells and underlines the validity of the APOD assay.
We now calculated the cutoff between scrotal-derived
control GFs from group 1 (adults and children together)
and the corresponding labioscrotal-derived GFs from AIS
individuals in group 3 (CAIS and PAIS together). Conse-
quently, an APOD induction below 2.29 represents a form
ofandrogen resistancewitha sensitivityof100%anda spec-
ificity of 97.67% and indicates that the two groups are sep-
arable with high confidence (Figure 2, A and B, and Supple-
mental Figure 8A).
From the clinical perspective, it is of much greater rel-
evance to distinguish AIS from other forms of DSD rather
than from clinically unsuspicious male controls. We cal-
culated a cutoff between labioscrotal-derived GFs from
group 2 (molecular defined DSD other than AIS) and
group 3 (AR-CDS mutation positive AIS) of 2.36-fold
APOD induction.Hence, aDHT-mediatedAPOD induc-
tion less than 2.36 distinguishes genetically proven AIS
from other molecular-defined DSDs with a sensitivity of
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100% and a specificity of 93.33% (Figure 2, A and B, and
Supplemental Figure 8B).
When analyzing foreskin/labia minora-derived GFs,
theAPODassay couldagain reliably separatemale control
fibroblasts (group 1) and GFs from AIS individuals har-
boring an AR-CDS mutation (group 3) (Figure 2C). A
cutoff of 2.36-fold APOD induction was determined for
foreskin/labia minora-derived tissue with 100% sensitiv-
ity and specificity (Figure 2, C and D, and Supplemental
Figure 8C). The averageDHT-mediatedAPOD induction
in CAIS was 0.97 (noAPOD induction) and 1.92 in PAIS
(Figure 2B). Although GFs from the individuals of group
2 showed an as high APOD induction as male controls
(group 1) (Figure 2C), no cutoff
could be calculated because there
were not enough corresponding
foreskin-derived GF strains avail-
able in our DSD-GF biobank. When
testing two GF strains derived from
congenital adrenal hyperplasia indi-
viduals carrying CYP21A2 muta-
tions andhavinga46,XXkaryotype,
their APOD response to DHT was
comparable with that of male con-
trols, confirming that the AR can be
activated by DHT in GF indepen-
dently of the chromosomal sex (Fig-
ure 2, A and B).
We than examined whether GFs
derived from genetically proven
CAIS and PAIS individuals within
group 3 could be distinguished from
each other by the APOD assay.
When comparing DHT-mediated
APOD induction, we found a signif-
icant difference between PAIS and
CAIS in both labioscrotal and labia
minora/foreskin-derived tissues (P
.01). However, therewas some over-
lap due to a few GF cultures (Figure
2,AandC).OneGFcell line carrying
a p.Val867Met mutation in the li-
gand binding domain of the AR de-
rived from a CAIS individual still
showed residual APOD induction.
Interestingly, when using lower DHT
concentrations, APOD induction
was abolished (Figure 3A). Labiami-
nora-derived GFs from another
CAIS individual bearing the muta-
tion p.Tyr782Asp, again located in
the AR-ligand binding domain, also
showed residual APOD induction.
However, this partial activity was even present at lower
DHT concentrations (Figure 3B). A third GF cell line was
derived from an individual with predominantly female
external genitalia and therefore PAIS, carrying a
p.Leu174stop mosaic. The latter was present in 94% of
the cultured GFs according to the NGS reads, which is
most likely the cause for complete abolishment of DHT-
mediated APOD induction despite the PAIS phenotype.
We also comparedAPOD induction between GFs har-
boring nonsense or missense mutations in the AR protein.
Nonsensemutations (stop or frame shift mutations) never
showed anyAPOD induction and always belonged to the
A B
C D
Figure 2. DHT-dependent, AR-induced APOD mRNA expression represented as the ratio
between ethanol (EtOH)- and DHT-treated GFs. A, Scrotum-derived male controls (vasectomy,
orchidopexy [group 1]), labioscrotal derived molecular defined DSDs (other DSDs [group 2]), and
AR-CDS mutation-positive AIS (CAIS, PAIS [group 3]). B, Depiction of cutoff values between male
controls (vasectomy and orchidopexy) and AR-CDS mutation-positive AIS (CAIS and PAIS) of 2.29
(100% sensitivity, 97.7% specificity, P  .0001) and between the same AR-CDS mutation-
positive AIS and molecular defined DSDs (other DSDs) of 2.36 (100% sensitivity, 93,3%
specificity, P  .0001). C, Foreskin-derived male controls (circumcision [group 1]) and molecular-
defined DSDs (other DSDs [group 2[) as well as AR-CDS mutation-positive AIS (CAIS, PAIS [group
3]). D, Depiction of the cutoff value between male controls (circumcision) and AR-CDS mutation-
positive AIS (CAIS and PAIS) of 2.36 (100% sensitivity, 100% specificity, P  .0001). Means and
SDs are included as error bars. Values of P  .001 are denoted by three stars, and those values of
P  .01 are denoted by two stars. Among the DSD diagnoses other than AIS, empty squares
represent SRD5A2, horizontally half-filled squares represent HSD17B3, vertically half-filled
squares represent CYP17A1, crossed squares represent CYP21A2, and dotted squares represent
NR5A1 mutations.
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CAIS group (apart from the p.Leu174stop mosaic),
whereas missense mutations had a variableAPOD induc-
tion andwere present in both PAIS- andCAIS-derivedGFs
(see Supplemental Tables 1 and 2).
In conclusion, the APOD assay does distinguish CAIS
individuals from PAIS individuals, albeit with slightly
lower sensitivity (88.2%) and specificity (90%) (Supple-
mental Figure 8D).
AR activity in AR-CDS mutation-negative GFs from
individuals with suspected diagnosis of AIS
(group 4)
We then analyzed the large group of AR-CDS muta-
tion-negative GFs derived from individuals with no pre-
viously established DSD diagnosis (group 4) using the
APOD assay and applied the above calculated cutoffs.
Looking at labioscrotal-derived GFs, 24% (n  8) of fi-
broblast cultures fromgroup4 fell below the cutoff of 2.29
and therefore have to be defined as functionally androgen
resistant (Figure4AandSupplementalTable1).Oneof the
GF cultures was from an individual with the suspected
clinical diagnosis of CAIS and showed strongly reduced
APOD induction. In contrast, the remaining76%(n25)
GF cell lines showed anAPOD induction above the cutoff
and had an AR activity comparable with that of control
groups 1 and 2 (Figure 4A). Therefore, these GF cell lines
have to be defined as normally androgen responsive. An-
alyzing the foreskin/labia minora-derived GFs in group 4,
the majority (69%, n  9) fell below the cutoff of 2.36.
Again, these cultures have to be defined as androgen in-
sensitive on a functional basis (Figure 4B and Supplemen-
tal Table 2). The remaining 31%of foreskin/labia minora
GF cultures (n  4) behaved like male foreskin controls
(group 1) in terms of APOD induction, and hence, an-
drogen insensitivity can be ruled out. In summary, 17 of
the 46 GFs from group 4 have functionally proven andro-
gen resistance based on androgen-induced APOD tran-
scription despite the absence of an AR-CDS mutation.
Molecular characterization of the AR-CDS
mutation-negative but functionally
androgen-resistant GFs
Finally, we wanted to know whether mutations de-
tected within the AR locus but outside the AR-CDS in
individuals of group 4 could potentially have influenced
AR activity. Of the 17 AR-CDS-mutation-negative, an-
drogen-resistantGFs, nine had one ormore not annotated
SNPs outside the AR-CDS, whereas eight had only previ-
ously annotated and clinically unsuspicious SNPs in the
region covered by our NGS approach. The distribution
of the nonannotated SNPs along the analyzed AR locus
is shown in Figure 5A. We speculated that a low APOD
induction could be due to a reduced AR protein expres-
sion or stability in these GFs. We checked the AR pro-
tein levels in all the 17 GF cultures and compared them
with their appropriate control groups (scrotal and fore-
skin derived GFs) (Figure 5, B and C, and Table 1). A
lower AR protein expression was seen in four GF of the
AR-mutation-negative, androgen-resistant group, indi-
cating that AR protein expression was impaired in these
cases. Two of these four individuals had nonannotated
SNPs outside the CDS (Table 1). In conclusion, we show
that reduced AR protein expression or stability can ex-
plain a reducedAPOD induction in about one-fourth of
the analyzed cases.
Discussion
Functional assays for AR activity in GFs have been de-
scribedbefore (16). Lacking a target gene for theAR,how-
ever, they were dependent on the transfection of exoge-
A
B
Figure 3. DHT-dependent, AR-induced APOD induction in response
to different DHT concentrations in the culture media. A, GF-11, GF-16,
and GF-35 are scrotum-derived male control GFs (Supplemental Table
1). GFs derived from a CAIS patient carrying the p.Ser310fs mutation
served as negative control. The p.Val867Met mutation is shown in
black. B, GF-120, GF-123, and GF-124 are foreskin-derived male
control GFs (Supplemental Table 2). GFs derived from a CAIS patient
carrying the p.Ser220fs mutation served as the negative control. The
p.Tyr782Asp mutation is shown in black.
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nous reporter constructs to monitor endogenous AR
activity.We here provide the APOD assay as a tool for the
functional characterization of cellular AR function inGFs
derived fromDSDpatients.Wevalidate its diagnostic suit-
ability in a very large cohort using male controls and var-
ious molecular well-defined DSD patients other than AIS
as well as several genetically proven classical AIS individ-
uals. The resulting diagnostic cutoffs not only helped to
exclude the diagnosis of AIS inmany cases but also lead to
the identification of an androgen-resistant but AR-CDS-
negativenewclassofAIS,whichwesuggest to callAIS type
II. This is not only a significant addition to the current
classification of 46,XY DSDs but also a starting point for
a better understanding of AR signal-
ing, including the identification of
new AR cofactors in future clinical
and molecular DSD studies.
Whereas the APOD assay sepa-
rates classical AIS from male con-
trols with high sensitivity and speci-
ficity, the separationwas slightly less
specific when comparing classical
AIS from defined DSD diagnoses
other than AIS. In fact, one individ-
ual with documented 5-reductase
(5RD) deficiency (group2) showed
reduced AR activity in the APOD as-
say. A possible explanation could be
that this individual has a defect both
inDHT synthesis and in androgenac-
tion. An additional 5RD deficiency
may also be responsible for the CAIS
phenotype of an individual carrying a p.Tyr781Aspmutation
in the ligand binding domain of the AR because biochem-
ical data indicate reduced 5RD activity in the GFs of this
patient (identification in C31 [17]). Both the residual
APOD in induction shown in this paper and in previously
published DHT binding and dissociation studies (17) in-
dicate only an incomplete loss of AR function in this in-
dividual despite a complete female phenotype.
Also, theAPODassaydidnot distinguishbetweenPAIS
and CAIS in all cases. This overlap may be affected by
specific functional and molecular conditions in some in-
dividual GF cultures. In GFs from a CAIS individual car-
rying a p.Val867Metmutation in the
AR ligand binding domain, we ob-
served residual APOD induction
with 10 nM DHT despite a clinical
CAIS. Interestingly, no APOD in-
duction was measured when using 1
nM DHT, suggesting that the CAIS
phenotype might have originated
from low local genital DHT concen-
trations during embryogenesis. This
observation is supported by the lit-
erature associating this mutation
with different AIS phenotypes, rang-
ing from CAIS through PAIS to
MAIS (14). Another phenomenon
with functional relevance for the
APOD assay may be the presence of
somatic mosaicism, which is an ap-
parently frequent condition in AIS
due to the high new mutation rate
(18, 19). In the PAIS subgroup within
A B
Figure 4. DHT-dependent, AR-induced APOD expression in AR-CDS-negative individuals with
clinically suspected androgen resistance (group 4) derived from scrotum/labia majora (A) and
from foreskin/labia minora (B). Suspected androgen-resistant GFs of group 4 are divided into mild
androgen resistance (MAIS, micropenis), partial androgen resistance (PAIS, ambiguous external
genitalia), and complete androgen resistance (CAIS, completely female external genitalia).
Included are means and SDs. For comparison, the tissue-specific controls and AR-CDS mutation-
positive GFs are shown as well. The calculated cutoffs are drawn as dotted lines.
A
B C
Figure 5. Analysis of AR-CDS mutation-negative but functionally androgen-insensitive GF. A,
Distribution of potentially damaging mutations in the sequenced region outside the AR-CDS. B,
AR protein expression in male scrotum-derived controls and AR-CDS mutation-negative but
functionally androgen-insensitive labioscrotal GFs. C, AR protein expression in male foreskin-
derived controls and AR-CDS mutation-negative but functionally androgen-insensitive GFs.
Included are means and SDs.
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group 3 of our study, one cell line contained a p.Leu174stop
mosaic (20) present in 94%of the culturedGFs according to
theNGS reads.NoAPOD induction could be detected,well
in line with the high percentage of the mutation in this PAIS
cell culture. Hence, whereas the APODassay correctly iden-
tifiedAIS in this situation, somaticmosaicismmay influence
the detected level of functional impairment,whichmaybe in
contrast to the clinical phenotype. We have previously de-
scribed this phenomenon of discrepancy betweenmolecular
studies and the clinical phenotype inmosaicAIS, using other
functionalapproaches(19,21).Ultimately,duetothe limited
information regarding the exact AIS grades of the genital
phenotypes in ourDSD-GF biobank (eg, according toQuig-
ley et al [22] or to Ahmed et al [23]), we cannot provide a
meaningful AIS grade/APOD assay correlation to date. The
APOD assay is therefore currently not a statistically proven
tool for assessing the quantitative extent of androgen resis-
tance in a given individual with DSD.
By analyzing sequencing data of the AR locus outside
the AR-CDS, we could detect as-yet nonannotated SNPs
within potentially regulatory regions. Some of these SNPs
are potential candidates for influencing AR activity be-
cause they are paralleled by reduced AR protein expres-
sion in the corresponding GF cultures, which could ex-
plain the lower AR activity in the AIS type II individuals.
Interestingly, we previously detected a mutation in the
5untranslated region of the AR in an individual having
CAIS and experimentally showed that this mutation is
sufficient to strongly reduce AR protein levels and AR
activity (24). This underlines the importance of detection
of potential mutations outside the AR-CDS. Another
promisinggroupof factors outside theARgene region that
might contribute toAIS type II areARcofactors,whichare
needed for proper AR activity (5, 6). Numerous cofactors
of the AR have been described in prostate cancer (25), but
a coregulator that exclusively regulates the AR has not
been described so far. Since the AR gene was cloned in
1988 (26, 27), only one single case of disrupted AR acti-
vation through a coactivator defect has been reported in a
CAIS individual (28), but this coactivator has never been
identified. No further case has since been described.
We do not yet know whether the AIS type II cohort
identified in this study has a monogenic origin or whether
multiple aberrant genes may contribute to this entity. Ex-
ome sequencing of the AR-CDS-negative AIS type II co-
hort in comparison with the other three cohorts of this
study is one of the next important experimental steps
planned. Furthermore, we cannot exclude that mild func-
tional AIS type II may play a role as secondary modifier
contributing to a DSD phenotype, even in certain molec-
ular-defined DSDs and in unknown DSDs. This is sup-
ported by previous reports documenting the existence of
Table 1. List of AR-CDS Mutation-Negative but Functionally Androgen-Insensitive GFs
GF
Origin of
Biopsy
SNP (Chromosome
Reference>Alternate)
APOD
Induction
AR Protein
Expression Encode Regulation (hg19)
GF-89 S Nothing 1.26 0.00
GF-107 S ChrX:66912572 GA 2.27 0.19 Strong enhancer in HSMM
GF-104 S Nothing 1.30 0.38
GF-105 S Nothing 1.64 0.40
GF-90 S ChrX:66839548 GA 2.26 0.68 Strong enhancer in HUVEC
GF-109 S ChrX:66811878 TC 1.64 0.78 Polycomb repressed in GM12878, K562,
H1-hESC, HELA, HUVEC, HepG2
GF-86 S Nothing 2.25 0.95
GF-118 S ChrX:66922786 AG 1.25 1.05 /
GF-164 F ChrX:66877648 GA 1.52 0.13 Polycomb repressed in GM12878, K562,
H1-hESC, HELA, HUVEC, HepG2
GF-158 F Nothing 1.76 0.48
GF-162 F ChrX:66864354 AG; ChrX:66860551
CA
2.08 0.82 Polycomb repressed in GM12878, K562,
H1-hESC, HELA, HUVEC, HepG2
GF-160 F ChrX:66795584 AG; ChrX:66817032
3bp del
2.11 0.88 Polycomb repressed in GM12878, K562,
H1-hESC, HELA, HUVEC, HepG2;
Pol2-associated transcription in H1-
hESC
GF-159 F ChrX:66933579 GC 1.95 0.90 Transcription in HUVEC
GF-168 F Nothing 2.17 1.00
GF-157 F Nothing 2.23 1.09
GF-163 F ChrX:66833033 AG 2.22 1.14 Strong enhancer in HUVEC and HSMM
GF-166 F Nothing 1.11 1.61
Abbreviations: GM12878, B-lymphocyte; HELA, cervical carcinoma cells; ; HepG2, liver hepatocellular carcinoma cells H1-hESC, H1 human
embryonic stem cells; HSMM, human skeletal muscle cells and myoblasts; HUVEC, human umbilical vein endothelial cells; K562, leukemia cell line;
S, scrotal derived GF; F, foreskin derived GF.
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more than one compromised molecular factor in the same
DSD individual (29–31). According to Cox et al (32), asso-
ciated conditions occur in about a quarter of analyzed DSD
cases. Looking specifically at cases with suspected androgen
insensitivity syndrome, 11% anomalies were reported. In
our AR-CDS-negative in AIS type II cohort, we found doc-
umentedminor syndromic signs in 4 of 46 cases, hence 9%.
In addition, prenatal conditions leading to low birth weight
may have programming effects on androgen responsiveness
of genital cells as a correlation of a low birth weight and a
PAIS-like phenotype in individuals without anAR genemu-
tation has been described before (33).
Currently our data are based on retrospective analyses
of fibroblasts obtained from our DSD biobank, but they
can nevertheless be of potential value for the clinical en-
docrinologist. Apart from being an explanation for the
phenotypic development of a DSD individual, reduced
APOD inductionmay be associatedwith a reduced future
AR sensitivity during puberty and may influence clinical
response to androgen treatment. Prospective data are
needed to correlate APOD expression with clinical out-
come parameters in affected individuals. Given the high
significance of the data provided in this manuscript, the
scientific community in DSD research should revisit the
clinical indication of a diagnostic genital skin biopsy in
specific unclear DSD cases.
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